Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0 ~ 102.0% Factory

Lenvatinib Mesylate (CAS: 857890-39-2) mai hanawa na baka da yawa na VEGFR1-3, FGFR1-4, PDGFR, KIT, da RET, tare da ayyukan antitumor masu ƙarfi.Lenvatinib Mesylate shine mai hana tyrosine kinase (RTK) mai hanawa wanda ke da zaɓi don VEGFR2.Yana nuna aikin antineoplastic, kuma an nuna shi don kula da marasa lafiya tare da maimaitawa na gida ko metastatic, ci gaba, radioactive iodine (RAI) -refractory differentiated thyroid cancer.Hukumar Abinci da Magunguna ta Amurka (FDA) ta fara amincewa da Lenvatinib Mesylate a ranar 13 ga Fabrairu, 2015, sannan Hukumar Kula da Magunguna da Magunguna ta Japan (PMDA) ta amince da ita a ranar 26 ga Maris, 2015, kuma Hukumar Kula da Magunguna ta Turai (EMA) ta amince da shi. Mayu 28, 2015. An haɓaka shi kuma an sayar dashi azaman Lenvima® ta Eisai.Lenvatinib Mesylate wani nau'in mai karɓa ne na baka mai yawa na tyrosine kinase inhibitor tare da yanayin ɗauri na musamman wanda ke hana ayyukan kinase na masu karɓar haɓakar haɓakar ƙwayar cuta (VEGF), baya ga sauran proangiogenic da kuma hanyar oncogenic tyrosine kinases da ake tunanin shiga cikin haɓakar ƙari. .An nuna shi don maganin ciwon daji na thyroid mai ban sha'awa na radioiodine-refractory.LenvimaAna amfani da ita da kanta don magance bambancin ciwon thyroid (DTC), nau'in ciwon daji na thyroid wanda ba za a iya yin magani da shi da iodine radioactive ba kuma yana ci gaba.Ana amfani da LENVIMA tare da wani magani da ake kira everolimus don kula da manya masu irin ciwon koda da ake kira Advanced Renal cell carcinoma (RCC) bayan wata hanya ta magani tare da wani maganin ciwon daji.